IMVT
Company Description
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Track Record
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (505.61M) | (413.84M) | (259.34M) | (210.96M) | (156.73M) | (107.43M) | (66.39M) | (448) | (136.74M) |
| EPS | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0.00 | -13.68 |
| Free Cash Flow | (407.32M) | (376.63M) | (214.59M) | (188.39M) | (106.37M) | (83.54M) | (53.39M) | (28.60M) | (128.30M) |
| FCF / Share | -2.23 | -2.48 | -1.55 | -1.53 | -0.97 | -0.95 | -1.24 | -1.99 | -12.83 |
| Operating CF | (407.31M) | (375.87M) | (214.23M) | (188.19M) | (106.11M) | (83.33M) | (53.36M) | (28.55M) | (128.30M) |
| Total Assets | 957.57M | 776.22M | 666.71M | 405.84M | 515.56M | 412.49M | 109.39M | 405,000 | 113,170 |
| Total Debt | 72,000 | 98,000 | 138,000 | 1.22M | 2.36M | 3.42M | 3.19M | 300,000 | 0 |
| Cash & Equiv | 902.11M | 713.97M | 635.37M | 376.53M | 493.82M | 400.15M | 100.57M | 325,000 | 0 |
| Book Value | 852.59M | 707.45M | 617.76M | 362.49M | 469.82M | 391.48M | 94.07M | 24,552 | (1.50M) |
| Return on Equity | -0.59 | -0.58 | -0.42 | -0.58 | -0.33 | -0.27 | -0.71 | -0.02 | N/A |
| Metric | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (153.22M) | (147.86M) | (110.64M) | (126.50M) | (120.61M) | (106.45M) | (111.12M) | (109.12M) | (87.15M) | (75.32M) | (51.42M) | (58.66M) |
| EPS | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 | -0.64 | -0.76 | -0.74 | -0.60 | -0.52 | -0.36 | -0.45 |
| Free Cash Flow | (124.41M) | (95.07M) | (92.33M) | (102.52M) | (117.41M) | (110.84M) | (100.57M) | (88.84M) | (76.38M) | (59.85M) | (47.23M) | (60.09M) |
| FCF / Share | -0.61 | -0.47 | -0.51 | -0.59 | -0.69 | -0.73 | -0.68 | -0.61 | -0.52 | -0.41 | -0.33 | -0.46 |
| Operating CF | (124.41M) | (95.06M) | (92.33M) | (102.52M) | (117.41M) | (110.64M) | (100.39M) | (88.65M) | (76.20M) | (59.70M) | (47.10M) | (60.06M) |
| Total Assets | 852.49M | 957.01M | 1.05B | 582.96M | 661.44M | 776.22M | 420.93M | 515.71M | 589.68M | 666.71M | 711.45M | 292.07M |
| Total Debt | 0 | 72,000 | 0 | 0 | 0 | 98,000 | 23,000 | 47,000 | 69,000 | 138,000 | 306,000 | 614,000 |
| Cash & Equiv | 797.80M | 902.11M | 994.52M | 521.87M | 598.91M | 713.97M | 374.69M | 472.94M | 560.00M | 635.37M | 690.94M | 269.93M |
| Book Value | 735.39M | 852.59M | 986.13M | 519.71M | 608.54M | 707.45M | 352.62M | 449.05M | 544.66M | 617.76M | 679.34M | 251.81M |
| Return on Equity | -0.21 | -0.17 | -0.11 | -0.24 | -0.20 | -0.15 | -0.32 | -0.24 | -0.16 | -0.12 | -0.08 | -0.23 |
